10-QHealthcare

Vertex Pharmaceuticals Inc

VRTX · Period ending 2026-09-30 · Filed 2026-11-03 · Updated

In short

Vertex Pharmaceuticals Inc (VRTX) has revenue up 8.9% to $12.0B year on year. Its net margin is 32.9%, and it trades at 35.3× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$515.02

Market Cap

$130.6B

P/E (TTM)

33.1x

Price ÷ earnings per share

P/B

6.2x

Price ÷ book value

P/S (TTM)

10.1x

Price ÷ revenue per share

Beta

0.28

Low volatility vs market

PEG Ratio

2.2x

P/E ÷ earnings growth rate

52-Week Range

$412.27$515.02 now$568.67

Decision Context

The reverse DCF implies growth expectations well above historical averages. Fundamentals need to accelerate significantly to justify the current price. Consider the margin of safety before sizing a position.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

VRTX vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — VRTX

Inflationary Boom
✦

Strengths

  • Net Income: $4.0B (+838.1% YoY) — Profit grew 838% — the company kept more of each dollar earned.

  • Operating Cash Flow: $3.6B (+837.2% YoY) — Operating cash flow grew 837% — the business generated more cash from day-to-day operations.

  • EPS (Diluted): $15.32 (+836.5% YoY) — Earnings per share rose 837% — each share earned more.

  • Total Assets: $25.6B (+13.8% YoY) — Total assets grew 14% — the company's resource base expanded.

  • Revenue: $12.0B (+8.9% YoY) — Revenue grew 9% — the company sold more goods or services than the prior year.

◈

Weaknesses

No material weaknesses flagged.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

No significant threats flagged.

Year-over-Year Changes

Net Income

$4.0B

was -$535.6M

+838.1%

Profit grew 838% — the company kept more of each dollar earned.

Operating Cash Flow

$3.6B

was -$492.6M

+837.2%

Operating cash flow grew 837% — the business generated more cash from day-to-day operations.

EPS (Diluted)

$15.32

was $-2.08

+836.5%

Earnings per share rose 837% — each share earned more.

Total Assets

$25.6B

was $22.5B

+13.8%

Total assets grew 14% — the company's resource base expanded.

Revenue

$12.0B

was $11.0B

+8.9%

Revenue grew 9% — the company sold more goods or services than the prior year.

Technical Signals

Daily closes · 1-year data

Vertex Pharmaceuticals Inc: common questions

Is Vertex Pharmaceuticals Inc profitable?

Yes. Vertex Pharmaceuticals Inc made a net profit of $4.0B in its latest fiscal year (fiscal 2025), a net margin of 32.9%.

Is Vertex Pharmaceuticals Inc's revenue growing?

Yes. Revenue grew 8.9% year on year, to $12.0B.

What is Vertex Pharmaceuticals Inc's P/E ratio?

Vertex Pharmaceuticals Inc trades at 33.1× its trailing twelve-month earnings. In other words, the share price is about 33 times the profit per share the company earned over the past year.

Does Vertex Pharmaceuticals Inc pay a dividend?

No dividend is currently expected from Vertex Pharmaceuticals Inc, according to the latest market data.

Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — VRTX

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade VRTX

Links open broker research pages. Not an endorsement or recommendation.

Research Vertex Pharmaceuticals Inc

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.